Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of...

[cafead]

via

• Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMA
• Ninety-one percent of children were alive at month 48
• More than 95% maintained the ability to swallow - without treatment they would have required feeding support and majority would have died within 2 years
• Evrysdi is now approved in 99 countries with more than 8,500 patients treated globally

article source